<div id="readability-page-1"><p>Shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) hit a new 52-week high on Monday . The stock traded as high as $314.00 and last traded at $310.6340, with a volume of 23480 shares traded. The stock had previously closed at $305.71.</p><div><p><span></span><span>Get <strong>Krystal Biotech</strong> alerts:</span></p></div><h2>Analyst Upgrades and Downgrades</h2><ul><li>Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore</li></ul><p>KRYS has been the topic of several research analyst reports. Weiss Ratings upgraded Krystal Biotech from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research note on Thursday, April 9th. Bank of America boosted their price objective on Krystal Biotech from $288.00 to $318.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, January 22nd. Zacks Research cut Krystal Biotech from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Thursday, February 5th. Jefferies Financial Group increased their target price on Krystal Biotech from $310.00 to $371.00 and gave the company a &#34;buy&#34; rating in a report on Tuesday, February 17th. Finally, HC Wainwright  reissued a &#34;buy&#34; rating and set a $310.00 target price on shares of Krystal Biotech in a report on Monday, May 4th. Ten investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $324.11.</p><p><b>Get Our Latest Stock Analysis on Krystal Biotech</b></p><h2>Krystal Biotech Stock Up 2.1%</h2><ul><li>Krystal Clear: Krystal Biotech Clears Resistance in Good Volume</li></ul><p>The firm has a 50-day moving average of $263.06 and a two-hundred day moving average of $248.61. The company has a market capitalization of $9.20 billion, a PE ratio of 41.76 and a beta of 0.50. </p><p>Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The business had revenue of $116.36 million during the quarter, compared to analyst estimates of $112.11 million.  On average, equities research analysts expect that  Krystal Biotech, Inc. will post 7.98 EPS for the current year. </p><h2>Insider Transactions at Krystal Biotech</h2><p>In other news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $267.60, for a total transaction of $200,700.00. Following the completion of the transaction, the chief accounting officer directly owned 22,366 shares in the company, valued at $5,985,141.60. This trade represents a 3.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Daniel Janney sold 37,895 shares of Krystal Biotech stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $266.88, for a total value of $10,113,417.60. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 116,664 shares of company stock valued at $31,136,828. Corporate insiders own  13.10% of the company's stock. </p><h2>Institutional Trading of Krystal Biotech</h2><p>A number of institutional investors have recently bought and sold shares of KRYS. Royal Bank of Canada lifted its holdings in  Krystal Biotech by 145.2% during the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company's stock worth $294,000 after buying an additional 964 shares during the last quarter.  AQR Capital Management LLC grew its position in  Krystal Biotech by 29.9% in the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company's stock valued at $2,187,000 after buying an additional 2,792 shares during the last quarter.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of  Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company's stock worth $2,870,000 after buying an additional 688 shares in the last quarter.  Empowered Funds LLC purchased a new position in shares of  Krystal Biotech during the 1st quarter worth approximately $218,000.  Finally, Cetera Investment Advisers raised its stake in shares of  Krystal Biotech by 107.9% during the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company's stock worth $597,000 after buying an additional 2,255 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors. </p><h2>About Krystal Biotech</h2> (Get Free Report)<p>Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.  </p><p>The company's lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Krystal Biotech</li><li>Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader</li><li>5 Stocks Positioned to Benefit From the AI Inference Boom</li><li>Meta Platforms’ Wild Post-Earnings Swings: Where Analyst Price Targets Stand Now</li><li>3 Metals and Mining Stocks Riding the Commodity Supercycle</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Krystal Biotech Right Now?</h2><p>Before you consider Krystal Biotech, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.</p><p>While Krystal Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

KRYS

IBBQ

<p>Krystal Biotech (NASDAQ:KRYS) reached a new 52-week high of $314.00, closing at $310.63 with a trading volume of 23,480 shares. Analysts have upgraded the stock, with Weiss Ratings moving it from "hold" to "buy" and Bank of America raising its price target from $288 to $318. The company reported a quarterly EPS of $1.83, exceeding estimates, and has a market cap of $9.20 billion. Insider trading activity includes significant sales by executives, while institutional ownership stands at 86.29%.</p>

Market Beat

Krystal Biotech

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Bank of America

Jefferies Financial

ROYAL BANK OF CANADA

Bank of Montreal

Canadian Imperial Bank Comm

Annaly Capital Mgmt

Sculptor Capital

Arqit Quantum

Nano Labs

Mirrabooka Investments Ltd

Power Assets Holdings

Costa Group Holdings Ltd. TEMP

Impact Shares YWCA Women Empowerment

Nomura Holdings, Inc.

LG QRAFT AI-Powered US Large Cap Core ETF

Japan Investment Adviser Co., Ltd.

Cetus Capital Acquisition Corp.

Russell Investment Management LLC

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

ANNALY CAPITAL MANAGEMENT INC 6.95% FXD FLTG CUM RED PFD SR F 30/09/22

ANNALY CAPITAL MANAGEMENT INC 8.875 CUM PREF SER J

ANNALY CAPITAL MANAGEMENT INC 6.750% FXD TO FTG RATE CUM RED PRF SR I

ANNALY CAPITAL MANAGEMENT INC 6.50 CUM RED PFD STK FIX FLT SER G USD25

Arqit Quantum - CW26

POWER ASSETS

Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week High  - Here's Why